Western blot imaging aids research in major Spanish hospital

A Syngene multi-application imager is being utilised by scientists at a major hospital in Spain to accelerate Western blot analysis of proteins expressed by white blood cells post-vaccination. Researchers are using the system to analyse rapidly and accurately ECL-labelled chemiluminescent Western blots of cellular receptors and proteins expressed by neutrophils and leucocytes. This fundamental research is allowing the scientists to detect changes in protein expression post-vaccination and is providing information to make predictions about the efficacy of, and potential adverse events associated with, clinical vaccines.

The Syngene system is also fitted with an ultraviolet (UV) transilluminator and green, blue and infrared (IR) light-emitting diode (LED) lighting as the researchers also currently use the system to visualise ethidium bromide-stained DNA gels and may in future image and analyse fluorescent multiplex Western blots.

“We’re delighted to hear that our imaging system is being used to speed up vital research at a major Spanish hospital,” stated Dr Martin Biggs (Sales Manager, Syngene). “Their work is a great endorsement of how this innovative imaging technology can be used in an immunology laboratory to improve the throughput and quality of vaccine testing.”

 

Other news

Upcoming Events

Managing Difficult People

Holiday Inn, Kensington Forum, 97 Cromwell Road, London SW7 4DN
15 November 2018

War on Cancer 2018

The Waldorf Hilton, Aldwych, London WC2B 4DD
20 November 2018

Organisational Leadership Skills

Holborn, London
22-23 November 2018

Respiratory Microbiology - A Day of Inspiration

Royal Air Force Museum, Hendon
16 May 2019

Clinical and Laboratory Haemostasis 2019

The Atrium Conference Centre, Sheffield Hallam University
5-6 June 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Oct 2018

High-throughput HPV testing: NHSCSP approval secured

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.